Glucagon-like peptides 1 and 2 in health and disease: A review
Date
2013
Authors
Marathe, C.
Rayner, C.
Jones, K.
Horowitz, M.
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Journal article
Citation
Peptides, 2013; 44:75-86
Statement of Responsibility
Chinmay S. Marathe, Christopher K. Rayner, Karen L. Jones, Michael Horowitz
Conference Name
Abstract
The gut derived peptides, glucagon-like peptides 1 and 2 (GLP-1 and GLP-2), are secreted following nutrient ingestion. GLP-1 and another gut peptide, glucose-dependent insulinotropic polypeptide (GIP) are collectively referred to as 'incretin' hormones, and play an important role in glucose homeostasis. Incretin secretion shares a complex interdependent relationship with both postprandial glycemia and the rate of gastric emptying. GLP-1 based therapies are now well established in the management of type 2 diabetes, while recent literature has suggested potential applications to treat obesity and protect against cardiovascular and neurological disease. The mechanism of action of GLP-2 is not well understood, but it shows promise as an intestinotropic agent.
School/Discipline
Dissertation Note
Provenance
Description
Access Status
Rights
© 2013 Elsevier Inc. All rights reserved.